• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Biogen (BIIB) Is Down 6.7% After At-Home LEQEMBI Launch And New Alzheimer’s Data - Has The Bull Case Changed?

    Simply Wall St·07/15/2026 09:25:52
    Listen to the news
    • Eisai and Biogen recently reported that in the real-world three-year LEADER study, around 83% of early Alzheimer’s patients stayed stable or improved on LEQEMBI over roughly 17 months, with safety findings aligning with the existing U.S. label.
    • In parallel, the FDA cleared LEQEMBI IQLIK, a once-weekly subcutaneous autoinjector for at-home initiation and maintenance, and Biogen released encouraging Phase 2 data for its tau-targeting candidate diranersen, underscoring a multi-pronged push in Alzheimer’s beyond traditional clinic-based infusions.
    • Next, we’ll examine how at-home LEQEMBI IQLIK initiation could reshape Biogen’s investment narrative around Alzheimer’s access, growth, and risk concentration.

    The latest GPUs need a type of rare earth metal called Dysprosium and there are only 30 companies in the world exploring or producing it. Find the list for free.

    Biogen Investment Narrative Recap

    To own Biogen today, you generally have to believe that Alzheimer’s can offset pressure in older franchises and justify reinvestment in neurology. The clearest near term catalyst is how quickly physicians, payers, and patients adopt at home LEQEMBI IQLIK, while the biggest current risk remains Biogen’s reliance on a few high cost launches amid intensifying pricing and reimbursement pressure; this week’s Alzheimer’s updates sharpen, rather than remove, that trade off.

    The most relevant news here is the FDA’s approval of LEQEMBI IQLIK as a once weekly at home initiation option. That decision directly affects access and real world uptake, which now sit at the center of Biogen’s story as LEADER data and the CELIA tau readout push Alzheimer’s further into the core growth and risk conversation for the stock.

    Yet investors should also weigh how payer pushback on high cost Alzheimer’s care could limit the upside that LEQEMBI IQLIK appears to unlock for Biogen shareholders…

    Read the full narrative on Biogen (it's free!)

    Biogen's narrative projects $10.7 billion revenue and $2.2 billion earnings by 2029.

    Uncover how Biogen's forecasts yield a $219.27 fair value, a 14% upside to its current price.

    Exploring Other Perspectives

    BIIB 1-Year Stock Price Chart
    BIIB 1-Year Stock Price Chart

    Some of the most cautious analysts, who were assuming fairly flat revenue around US$9.8 billion and earnings of about US$1.8 billion by 2029, frame LEQEMBI’s access and pricing risk very differently from more optimistic views, so it is worth comparing those expectations to your own before you decide how this new Alzheimer’s news might shift the story.

    Explore 6 other fair value estimates on Biogen - why the stock might be worth over 2x more than the current price!

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your Biogen research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
    • Our free Biogen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Biogen's overall financial health at a glance.

    Curious About Other Options?

    Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.